Herbal treatment with uva ursi extract versus fosfomycin in women with uncomplicated urinary tract infection in primary care: a randomized controlled trial

2021-10 | journal article; research paper. A publication with affiliation to the University of Göttingen.

Jump to: Cite & Linked | Documents & Media | Details | Version history

Cite this publication

​Gágyor, I., Hummers, E., Schmiemann, G., Friede, T., Pfeiffer, S., Afshar, K. & Bleidorn, J. (2021). ​Herbal treatment with uva ursi extract versus fosfomycin in women with uncomplicated urinary tract infection in primary care: a randomized controlled trial. Clinical Microbiology and Infection27(10), ​1441​-1447​. ​doi: https://doi.org/10.1016/j.cmi.2021.05.032 

Documents & Media

License

Published Version

GRO License GRO License

Details

Authors
Gágyor, Ildikó ; Hummers, Eva ; Schmiemann, Guido; Friede, Tim ; Pfeiffer, Sebastian; Afshar, Kambiz; Bleidorn, Jutta
Abstract
Objective We explored whether initial treatment with the herbal drug uva ursi (UU) reduces antibiotic use in women with uncomplicated urinary tract infection (UTI) without increasing symptom burden and complication frequency compared with antibiotic treatment. Methods A double-blind randomized controlled trial was conducted in 42 family practices in Germany. The participants were adult women with suspected uncomplicated UTIs receiving either UU 105 mg 3 × 2 tablets for 5 days (intervention) or fosfomycin a 3-g single dose (control), and their respective placebos. Participants and investigators were blinded. The primary outcome included (1) antibiotic courses day 0–28 as superiority, and (2) symptom burden (sum of daily symptom scores) day 0–7, as non-inferiority outcome (margin 125%). Clinicaltrials.gov: NCT03151603. Results Overall, 398 patients were randomly allocated to groups receiving UU (n = 207) and fosfomycin (n = 191). The number of antibiotic courses was 63.6% lower (95% CI 53.6%–71.4%; p < 0.0001) in the UU group than in the fosfomycin group. The ratio of total symptom burden in the UU group compared with control was 136.5% (95% CI 122.7–151.9; p 0.95), failing non-inferiority. Eight women developed pyelonephritis in the UU group compared with two in the fosfomycin group (mean difference 2.8; 95% CI 0.2–5.9; p 0.067). Adverse events were similar between the groups. Discussion In women with uncomplicated UTIs, initial treatment with UU reduced antibiotic use but led to a higher symptom burden and more safety concerns than fosfomycin.
Issue Date
October-2021
Journal
Clinical Microbiology and Infection 
Organization
Institut für Allgemeinmedizin ; Institut für Medizinische Statistik 
ISSN
1198-743X
eISSN
1469-0691
Language
English

Reference

Citations


Social Media